Solid Biosciences Inc.
SLDB
$6.83
-$0.01-0.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 33.43% | 50.60% | 348.27% | 170.40% | 63.21% |
| Gross Profit | -33.43% | -50.60% | -348.27% | -170.40% | -82.46% |
| SG&A Expenses | 21.54% | 19.98% | 30.80% | 21.05% | 17.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 44.15% | 24.36% | 5.66% | -3.92% | -7.54% |
| Operating Income | -44.15% | -24.36% | -5.66% | 3.92% | 1.89% |
| Income Before Tax | -54.77% | -29.87% | -12.78% | -0.48% | 0.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -54.77% | -29.87% | -12.78% | -0.48% | 0.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -54.77% | -29.87% | -12.78% | -0.48% | 0.52% |
| EBIT | -44.15% | -24.36% | -5.66% | 3.92% | 1.89% |
| EBITDA | -44.85% | -25.10% | -6.53% | 3.63% | 1.79% |
| EPS Basic | 24.08% | 37.27% | 40.94% | 51.59% | 55.73% |
| Normalized Basic EPS | 24.14% | 37.31% | 47.78% | 55.95% | 57.91% |
| EPS Diluted | 24.08% | 37.31% | 40.98% | 51.62% | 55.75% |
| Normalized Diluted EPS | 24.14% | 37.31% | 47.78% | 55.95% | 57.91% |
| Average Basic Shares Outstanding | 95.11% | 105.27% | 98.89% | 104.96% | 112.79% |
| Average Diluted Shares Outstanding | 95.11% | 105.27% | 98.89% | 104.96% | 112.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |